Metabolic & Weight-Loss Research · Incretin Compound
Tirzepatide
A dual GIP/GLP-1 receptor agonist studied in weight-loss (obesity), incretin receptor-pharmacology, and metabolic mechanism research.
Tirzepatide is a synthetic peptide engineered to activate two incretin receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This “dual agonist” design is the basis for much of the research interest in the incretin field, where it is studied as a model molecule for combined-receptor pharmacology.
All information here reflects published trial and preclinical research and is provided for educational, research-use-only purposes. Tirzepatide is studied in laboratory and clinical research contexts; material on this page is not for human consumption and makes no representation about personal use.
Research areas
Dual-Receptor Mechanism
Engineered to co-activate GIP and GLP-1 receptors with a single molecule — the defining pharmacology studied across the incretin literature.
Incretin Signaling Research
Studied for how combined GIP/GLP-1 receptor activation influences insulin secretion and glucose handling in controlled settings.
Receptor-Pharmacology Studies
Research characterizes binding affinity and downstream signaling relative to single-receptor GLP-1 agonists.
Comparative Research
Frequently compared against single GLP-1 agonists and triple agonists in the research literature.
Recent research findings
- 2024Research continued characterizing dual-agonist receptor pharmacology and downstream incretin signaling.
- 2022Early and mid-stage pharmacology established the dual GIP/GLP-1 receptor activity profile.
- 2021Coskun et al. and related work detailed the molecular pharmacology of the dual-receptor mechanism.
Published Research & Citations
The research summarized above is drawn from published, peer-reviewed studies. Explore the 5 sources below — links open the abstract or, where marked, the full free article on the U.S. National Library of Medicine (PubMed / PMC).
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism, 2018. Free full text Open-access discovery paper characterizing the dual GIP/GLP-1 receptor mechanism in preclinical and early human work.
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020. Free full text Open-access study detailing tirzepatide's biased signaling at the GIP and GLP-1 receptors.
- Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2022. Free full text Open-access review of the dual-incretin receptor mechanism and its pharmacology.
- Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes. Diabetes Therapy, 2021. Free full text Open-access review of the receptor pharmacology and trial evidence base.
- de Mesmay, et al. Molecular pharmacology of the dual GIP/GLP-1 receptor agonist class. Peptides, 2023. Review of combined-incretin receptor signaling across the dual-agonist class.